share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/11/05 05:46

Moomoo AI 已提取核心訊息

Adial Pharmaceuticals announced the appointment of Vinay Shah as Chief Financial Officer, effective November 16, 2024, following Joseph Truluck's resignation. Shah brings over 25 years of pharmaceutical and healthcare financial experience, previously serving as CFO at Virpax Pharmaceuticals and Aravive Inc., where he helped raise over $150 million.Under the employment agreement, Shah will receive an annual base salary of $315,000 with a potential 30% discretionary bonus and 40,000 stock options. The three-year contract includes six months' severance for without-cause termination and twelve months' severance following a change of control.Truluck will remain with the company until November 15, 2024, and continue as a consultant through March 31, 2025. His separation agreement includes full salary through December 2024, 50% salary for Q1 2025, and $350 hourly consulting rate thereafter. The transition was not due to any disagreements regarding company operations or financial matters.
Adial Pharmaceuticals announced the appointment of Vinay Shah as Chief Financial Officer, effective November 16, 2024, following Joseph Truluck's resignation. Shah brings over 25 years of pharmaceutical and healthcare financial experience, previously serving as CFO at Virpax Pharmaceuticals and Aravive Inc., where he helped raise over $150 million.Under the employment agreement, Shah will receive an annual base salary of $315,000 with a potential 30% discretionary bonus and 40,000 stock options. The three-year contract includes six months' severance for without-cause termination and twelve months' severance following a change of control.Truluck will remain with the company until November 15, 2024, and continue as a consultant through March 31, 2025. His separation agreement includes full salary through December 2024, 50% salary for Q1 2025, and $350 hourly consulting rate thereafter. The transition was not due to any disagreements regarding company operations or financial matters.
Adial Pharmaceuticals宣佈任命Vinay Shah爲財務長,任命將於2024年11月16日生效,此前Joseph Truluck辭職。Shah在製藥和醫療保健財務方面擁有超過25年的經驗,曾擔任Virpax Pharmaceuticals和Aravive Inc.的財務長,在那裏他幫助籌集了超過15000萬美元。根據僱傭協議,Shah將獲得年薪315,000美元,並有可能獲得30%的酌情獎金和40,000個期權。三年合同包括六個月的無因終止賠償和在控制權變更後的十二個月賠償。Truluck將在2024年11月15日之前繼續留在公司,並將繼續作爲諮詢顧問,直至2025年3月31日。他的離職協議包括2024年12月前的全額薪水、2025年第一季度的50%薪水,以及此後每小時350美元的諮詢費。此項過渡並非由於與公司運營或財務問題的任何分歧。
Adial Pharmaceuticals宣佈任命Vinay Shah爲財務長,任命將於2024年11月16日生效,此前Joseph Truluck辭職。Shah在製藥和醫療保健財務方面擁有超過25年的經驗,曾擔任Virpax Pharmaceuticals和Aravive Inc.的財務長,在那裏他幫助籌集了超過15000萬美元。根據僱傭協議,Shah將獲得年薪315,000美元,並有可能獲得30%的酌情獎金和40,000個期權。三年合同包括六個月的無因終止賠償和在控制權變更後的十二個月賠償。Truluck將在2024年11月15日之前繼續留在公司,並將繼續作爲諮詢顧問,直至2025年3月31日。他的離職協議包括2024年12月前的全額薪水、2025年第一季度的50%薪水,以及此後每小時350美元的諮詢費。此項過渡並非由於與公司運營或財務問題的任何分歧。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息